Mariana Da Silva Ferreira

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition”.

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Blood(2020)10.1182/blood.2020008017

N/A

0DataRank · unranked

36 citations

Mandana T. Manzari, Laurie Herviou, Mariana Da Silva Ferreira, Connor J. Hagen, Hiroto Kiguchi +6 more

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors

Cell Reports Medicine(2021)10.1016/j.xcrm.2021.100350

N/A

0DataRank · unranked

24 citations

Scott K. Thompson, Roger A. Smith, Mariana Da Silva Ferreira, Zahra Asgari, Andrea Knežević +7 more

TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma

Nature Communications(2022)10.1038/s41467-022-33137-8

N/A

0DataRank · unranked

29 citations

Chiara M. Evans, Daniel Zakheim, Eren L. Chu, Alice Yunsi Refermat, Zahra Asgari +18 more

Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma

Nature Communications(2023)10.1038/s41467-023-37216-2

N/A

0DataRank · unranked

14 citations

Mariana Da Silva Ferreira, Tatiana Erazo, Man Jiang, Zahra Asgari, Elisa de Stanchina +3 more